Advanced Oncotherapy PLC Director Dealing (2009T)

TIDMAVO

RNS Number : 2009T

Advanced Oncotherapy PLC

03 January 2017

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, has today purchased 25,000 ordinary shares of 25 pence each in the Company ("Ordinary Shares") at a price of 87 pence per Ordinary Share.

Following this transaction, Dr Vanni now holds 823,946 Ordinary Shares representing 1.14% of the issued share capital of the Company.

 
  Advanced Oncotherapy Plc                www.avoplc.com 
  Dr. Michael Sinclair,            Tel: +44 20 3617 8728 
   Executive Chairman 
  Nicolas Serandour, CEO 
 
  Stockdale Securities (Nomad 
   & Joint Broker) 
  Antonio Bossi / David            Tel: +44 20 7601 6100 
   Coaten 
 
  Stifel Nicolaus Europe 
   (Joint Broker) 
  Jonathan Senior / Ben            Tel: +44 20 7710 7600 
   Maddison 
 
  Walbrook PR (Financial        Tel: +44 20 7933 8780 or 
   PR & IR)                           avo@walbrookpr.com 
  Paul McManus / Anna Dunphy     Mob: +44 7980 541 893 / 
                                   Mob: +44 7876 741 001

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBBGDBGSGBGRX

(END) Dow Jones Newswires

January 03, 2017 06:41 ET (11:41 GMT)

Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024